$CPRX
CATALYST PHARMACEUTICALS, INC. Stock $cprx

$cprx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000119312524134195 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$122.7M	$98.51M	$110.6M
YoY Change	23.23%	15.4%	81.98%
Cost Of Revenue	$15.41M	$12.52M	$15.81M
YoY Change	27.9%	25.88%	41.21%
Gross Profit	$107.3M	$85.99M	$94.76M
YoY Change	22.58%	14.01%	91.19%
Gross Profit Margin	87.45%	87.29%	85.7%
Selling, General & Admin	$40.73M	$46.94M	$42.04M
YoY Change	43.44%	57.94%	186.58%
% of Gross Profit	37.96%	54.59%	44.36%
Research & Development	$2.985M	$2.581M	$1.972M
YoY Change	-24.51%	-27.54%	-51.82%
% of Gross Profit	2.78%	3.0%	2.08%
Depreciation & Amortization	$9.435M	$86.00K	$9.143M
YoY Change	10.09%	24.64%	1386.67%
% of Gross Profit	8.79%	0.1%	9.65%
Operating Expenses	$43.72M	$49.52M	$53.07M
YoY Change	35.13%	48.8%	182.86%
Operating Profit	$54.25M	$27.13M	$41.69M
YoY Change	16.16%	-23.82%	35.36%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.542M	$1.963M	$5.015M
YoY Change	-14.95%	15.2%	127.23%
Pretax Income	$55.79M	$29.09M	$46.71M
YoY Change	15.0%	-22.04%	41.5%
Income Tax	$14.99M	$5.814M	$11.86M
% Of Pretax Income	26.88%	19.99%	25.4%
Net Earnings	$40.79M	$23.28M	$34.84M
YoY Change	8.03%	-21.28%	36.8%
Net Earnings / Revenue	33.24%	23.63%	31.51%
Basic Earnings Per Share	$0.35	$0.20
Diluted Earnings Per Share	$0.33	$0.19	$0.31
COMMON SHARES
Basic Shares Outstanding	118.1M	117.9M	106.6M
Diluted Shares Outstanding	124.7M	123.4M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$375.7M	$310.4M	$137.6M
YoY Change	110.13%	109.39%	-53.87%
Cash & Equivalents	$375.7M	$310.4M	$137.6M
Short-Term Investments	$0.00	$0.00	$0.00
Other Short-Term Assets	$23.55M	$13.75M	$12.54M
YoY Change	172.76%	98.23%	143.02%
Inventory	$18.01M	$19.95M	$15.64M
Prepaid Expenses
Receivables	$57.17M	$60.49M	$53.51M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$474.4M	$404.6M	$219.3M
YoY Change	96.88%	103.41%	-31.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.227M	$1.308M	$1.195M
YoY Change	2.0%	1.79%	41.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$13.08M	$15.35M	$16.49M
YoY Change
Other Assets	$39.89M	$38.28M	$36.54M
YoY Change	69.82%	89.09%	94.95%
Total Long-Term Assets	$231.9M	$242.1M	$250.8M
YoY Change	14.29%	16.21%	357.36%
TOTAL ASSETS
Total Short-Term Assets	$474.4M	$404.6M	$219.3M
Total Long-Term Assets	$231.9M	$242.1M	$250.8M
Total Assets	$706.4M	$646.7M	$470.1M
YoY Change	59.13%	58.8%	25.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.116M	$10.26M	$14.80M
YoY Change	60.96%	202.6%	272.2%
Accrued Expenses	$85.20M	$69.31M	$61.27M
YoY Change	77.2%	29.98%	14.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$92.32M	$79.57M	$76.06M
YoY Change	75.83%	40.31%	32.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.396M	$2.607M	$2.982M
YoY Change	-81.17%	-80.53%	-78.8%
Total Long-Term Liabilities	$2.396M	$2.607M	$2.982M
YoY Change	-81.17%	-80.53%	-78.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.32M	$79.57M	$76.06M
Total Long-Term Liabilities	$2.396M	$2.607M	$2.982M
Total Liabilities	$97.71M	$85.26M	$82.23M
YoY Change	42.42%	15.9%	9.34%
SHAREHOLDERS EQUITY
Retained Earnings	$185.3M	$144.5M	$121.3M
YoY Change	58.15%	81.98%	143.22%
Common Stock	$119.0K	$118.0K	$107.0K
YoY Change	11.21%	11.32%	1.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$608.7M	$561.4M	$387.9M
YoY Change
Total Liabilities & Shareholders Equity	$706.4M	$646.7M	$470.1M
YoY Change	59.13%	58.8%	25.15%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$40.79M	$23.28M	$34.84M
YoY Change	8.03%	-21.28%	36.8%
Depreciation, Depletion And Amortization	$9.435M	$86.00K	$9.143M
YoY Change	10.09%	24.64%	1386.67%
Cash From Operating Activities	$64.14M	$31.93M	$55.65M
YoY Change	108.54%	164.5%	38.85%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$199.0K	$93.00K
YoY Change		168.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$38.23M
YoY Change		-100.0%
Cash From Investing Activities	-$10.00K	-$199.0K	-$38.32M
YoY Change		-99.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.157M	141.0M	-665.0K
YoY Change	-640.65%	94563.76%	-129.52%
NET CHANGE
Cash From Operating Activities	64.14M	31.93M	55.65M
Cash From Investing Activities	-10.00K	-199.0K	-38.32M
Cash From Financing Activities	1.157M	141.0M	-665.0K
Net Change In Cash	65.28M	172.8M	16.66M
YoY Change	113.76%	-215.07%	-60.63%
FREE CASH FLOW
Cash From Operating Activities	$64.14M	$31.93M	$55.65M
Capital Expenditures	$10.00K	$199.0K	$93.00K
Free Cash Flow	$64.13M	$31.73M	$55.55M
YoY Change	108.51%	164.47%	38.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001369568
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-33057
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	CATALYST PHARMACEUTICALS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0837053
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	355 Alhambra Circle
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 801
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
CY2024Q1	dei	City Area Code CityAreaCode	305
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	420-3200
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	CPRX
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	118115079
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310411000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137636000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	60493000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53514000
CY2024Q1	us-gaap	Inventory Net InventoryNet	19953000
CY2023Q4	us-gaap	Inventory Net InventoryNet	15644000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13745000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12535000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	404602000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	219329000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2508000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1308000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1195000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184705000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	194049000
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	38276000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	36544000
CY2024Q1	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	15345000
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	16489000
CY2024Q1	us-gaap	Assets Assets	646676000
CY2023Q4	us-gaap	Assets Assets	470114000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10261000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14795000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69305000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61268000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	79566000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	76063000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3091000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3188000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2607000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2982000
CY2024Q1	us-gaap	Liabilities Liabilities	85264000
CY2023Q4	us-gaap	Liabilities Liabilities	82233000
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	118029526
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	118029526
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107121549
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107121549
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	118000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	107000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	416747000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	266488000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	144547000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	121272000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	561412000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	387881000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646676000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	470114000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98509000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85366000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12520000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9946000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2581000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3562000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46938000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29718000
CY2024Q1	cprx	Amortization Expenses Of Intangible Asset AmortizationExpensesOfIntangibleAsset	9344000
CY2023Q1	cprx	Amortization Expenses Of Intangible Asset AmortizationExpensesOfIntangibleAsset	6531000
CY2024Q1	cprx	Operating Expense OperatingExpense	71383000
CY2023Q1	cprx	Operating Expense OperatingExpense	49757000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	27126000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	35609000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1963000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1704000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	29089000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	37313000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5814000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7745000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23275000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29568000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.2
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116806117
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105561229
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123403626
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113986129
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23275000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29568000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	4000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	5000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23261000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29555000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	387881000
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140704000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8248000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1522000
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-204000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-14000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	23275000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	561412000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	300421000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2892000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1270000
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-477000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	29568000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	333661000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	23275000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	29568000
CY2024Q1	us-gaap	Depreciation Depreciation	86000
CY2023Q1	us-gaap	Depreciation Depreciation	69000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8248000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2892000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9344000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6531000
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1746000
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1519000
CY2024Q1	cprx	Accretion Of Discount AccretionOfDiscount	-153000
CY2023Q1	cprx	Accretion Of Discount AccretionOfDiscount	0
CY2024Q1	cprx	Non Cash Change In Right Of Use Asset NonCashChangeInRightOfUseAsset	68000
CY2023Q1	cprx	Non Cash Change In Right Of Use Asset NonCashChangeInRightOfUseAsset	64000
CY2024Q1	cprx	Acquired Inventory Samples Expensed From Asset Acquisition AcquiredInventorySamplesExpensedFromAssetAcquisition	0
CY2023Q1	cprx	Acquired Inventory Samples Expensed From Asset Acquisition AcquiredInventorySamplesExpensedFromAssetAcquisition	130000
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1144000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6979000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22963000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4309000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-577000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1210000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	191000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4534000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-584000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8474000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2422000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-89000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-82000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31925000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12070000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	199000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000
CY2024Q1	cprx	Payment In Connection With Asset Acquisition PaymentInConnectionWithAssetAcquisition	0
CY2023Q1	cprx	Payment In Connection With Asset Acquisition PaymentInConnectionWithAssetAcquisition	162293000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-199000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-162367000
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	204000
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	477000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1522000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1270000
CY2024Q1	cprx	Payment Of Liabilities Arising From Asset Acquisition PaymentOfLiabilitiesArisingFromAssetAcquisition	973000
CY2023Q1	cprx	Payment Of Liabilities Arising From Asset Acquisition PaymentOfLiabilitiesArisingFromAssetAcquisition	644000
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	141000000
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	296000
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141049000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	149000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	172775000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-150148000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137636000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	298395000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310411000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148247000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	65000
CY2024Q1	cprx	Liabilities Arising From Asset Acquisition LiabilitiesArisingFromAssetAcquisition	0
CY2023Q1	cprx	Liabilities Arising From Asset Acquisition LiabilitiesArisingFromAssetAcquisition	1915000
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Description of Business. </div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage, patient-centric biopharmaceutical company focused on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-licensing,</div> developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company currently markets three drug products, FIRDAPSE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> (amifampridine), FYCOMPA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> (perampanel), and AGAMREE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> (vamorolone). The Company is also currently seeking to further expand its product portfolio, with a focus on acquiring the rights to late-stage products to treat rare (orphan) central nervous system and adjacent rare (orphan) diseases. With an unwavering patient focus embedded in everything the Company does, it is committed to providing innovative, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">best-in-class</div></div> medications with the hope of making a meaningful impact on those affected by these conditions. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s New Drug Application (NDA) for FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food & Drug Administration (FDA), and FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> is commercially available in the United States (U.S.) as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals. In the third quarter of 2022, the FDA approved the Company’s supplemental New Drug Application approving an expansion of the FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> label to include pediatric patients (ages six and older). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the U.S. rights to FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> on January 24, 2023 and the Company began marketing FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> in the U.S. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2023, the Company completed its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an exclusive license for North America for AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div><div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"> </div>(vamorolone), a treatment for patients suffering with Duchenne muscular dystrophy (DMD). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities in those jurisdictions. Additionally, the Company will hold North American rights for any future approved indications of AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div>. AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div><div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"> </div>has previously received FDA Orphan Drug and Fast Track designations. On October 26, 2023, the FDA approved AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> oral suspension 40 mg/ml for the treatment of DMD in patients aged two years and older, and on March 13, 2024, the Company announced the U.S. commercial launch of AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div>. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its products. The Company has been able to fund its cash needs to date through offerings of its securities and from revenues from sales of its products. See Note 15 (Stockholders’ Equity). </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capital Resources </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on forecasts of available cash, the Company believes that it has sufficient resources to support the currently anticipated operations for at least the next 12 months from the date of this report. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business. <br/></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 9, 2024, the Company completed a public offering of 10 million shares of its common stock, raising net proceeds of approximately $140.7 million. The proceeds of the offering will be used to potentially acquire new products and for general corporate purposes. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is subject to risks and uncertainties that could affect its business in unforeseen ways. </div></div></div>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">USE OF ESTIMATES.</div></div> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </div></td></tr></table>
CY2024Q1	cprx	Maximum Maturity Period Of Cash And Cash Equivalent MaximumMaturityPeriodOfCashAndCashEquivalent	three months
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0
CY2023Q3	cprx	Asset Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	1414688
CY2023Q3	cprx	Asset Acquisition Percentage Of Outstanding Ordinary Shares AssetAcquisitionPercentageOfOutstandingOrdinaryShares	0.1126
CY2024Q1	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	15345000
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	16489000
CY2024Q1	cprx	Share Repurchases ShareRepurchases	<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">SHARE REPURCHASES.</div></div> In March 2021, the Company’s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $40 million of the Company’s common stock. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock’s par value entirely to retained earnings. All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div>
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2024Q1	cprx	Maximum Amortization Period Of Compensation Cost On Straight Line Basis MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis	P3Y
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: "Times New Roman"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">CONCENTRATION OF RISK. </div></div>The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company sells its products, FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> and AGAMREE<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div>, in the U.S. through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues related to this product. The Company sells its product, FYCOMPA<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">®</div> to major wholesalers, specialty pharmaceutical distributors, managed care organizations, and government agencies. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March 31, 2024, the Company had three FDA approved products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div>. The Company expects FIRDAPSE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> and the recently acquired products FYCOMPA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> and AGAMREE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> to constitute virtually all of the Company’s product revenue for the foreseeable future. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company relies exclusively on third parties to formulate and manufacture its products and any future drug candidates. The commercialization of its products and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div>. The Company relies on the same third-party manufacturers for FYCOMPA® as utilized by Eisai prior to the Company’s acquisition in January 2023. It also relies on Santhera as its sole source of supply for AGAMREE<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div>. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of its drugs. </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The following table illustrates the approximate percentage of the Company’s total net product revenue attributed to the Company’s largest customers for the periods presented: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"> <tr> <td style="width: 78%;"><div style="display:inline;"></div></td> <td style="width: 8%; vertical-align: bottom;"><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> <td><div style="display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended<br/>March 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr> <td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Customer A</div></div></div> </td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">69.1</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">67.4</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Customer B</div></div></div> </td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">— </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">32.6</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 78%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Customer C</div> </td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">10.5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">— </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Customer D</div> </td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">10.1</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">— </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></div> </td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">89.7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;">100.0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;">% </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 78%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> <td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></td> </tr> </table> <div style="width: 9%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 9%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During 2023, the Company sold FYCOMPA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">®</div> is being sold and distributed through a 3PL organization. </div></div></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div>
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116806117
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105561229
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6597509
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	8424900
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123403626
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113986129
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5200000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1300000
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RECLASSIFICATIONS.</div></div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div></td></tr></table>
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	0
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
CY2024Q1	cprx	Amortized Cost Before Unrealized Gains And Losses AmortizedCostBeforeUnrealizedGainsAndLosses	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	94523000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	18000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
CY2023Q4	cprx	Amortized Cost Before Unrealized Gains And Losses AmortizedCostBeforeUnrealizedGainsAndLosses	94505000
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1144000
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1144000
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Tax OtherComprehensiveIncomeLossBeforeReclassificationsTax	14000
CY2024Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Tax OtherComprehensiveIncomeLossBeforeReclassificationsTax	13000
CY2023Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5926000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1910000
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3963000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4573000
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10064000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9161000
CY2024Q1	us-gaap	Inventory Net InventoryNet	19953000
CY2023Q4	us-gaap	Inventory Net InventoryNet	15644000
CY2024Q1	cprx	Prepaid Manufacturing Expense PrepaidManufacturingExpense	2005000
CY2023Q4	cprx	Prepaid Manufacturing Expense PrepaidManufacturingExpense	2005000
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	307000
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1238000
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	952000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1332000
CY2024Q1	cprx	Prepaid Subscription Fees PrepaidSubscriptionFees	1937000
CY2023Q4	cprx	Prepaid Subscription Fees PrepaidSubscriptionFees	1299000
CY2024Q1	cprx	Prepaid Research Fee PrepaidResearchFee	1513000
CY2023Q4	cprx	Prepaid Research Fee PrepaidResearchFee	1500000
CY2024Q1	cprx	Prepaid Commercial Expenses PrepaidCommercialExpenses	2951000
CY2023Q4	cprx	Prepaid Commercial Expenses PrepaidCommercialExpenses	3038000
CY2024Q1	cprx	Due From Collaborative And Licencing Arrangements DueFromCollaborativeAndLicencingArrangements	143000
CY2023Q4	cprx	Due From Collaborative And Licencing Arrangements DueFromCollaborativeAndLicencingArrangements	138000
CY2024Q1	cprx	Prepaid Conference And Travel Expenses PrepaidConferenceAndTravelExpenses	844000
CY2023Q4	cprx	Prepaid Conference And Travel Expenses PrepaidConferenceAndTravelExpenses	771000
CY2024Q1	cprx	Prepaid Copay Assistance Program PrepaidCopayAssistanceProgram	1561000
CY2023Q4	cprx	Prepaid Copay Assistance Program PrepaidCopayAssistanceProgram	863000
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1532000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	351000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13745000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12535000
CY2024Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	5 years
CY2024Q1	cprx	Operating Lease Liability Under Finance Leases OperatingLeaseLiabilityUnderFinanceLeases	0
CY2024Q1	cprx	Before Agreement Of Company Leased Spaces BeforeAgreementOfCompanyLeasedSpaces	7800
CY2024Q1	cprx	After Agreement Of Company Leased Spaces AfterAgreementOfCompanyLeasedSpaces	10700
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	108000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	108000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	129000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	125000
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22000
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2508000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	377000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3091000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3188000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3468000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3557000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0451
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0451
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	394000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	537000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	553000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	570000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	587000
CY2024Q1	cprx	Lessee Operating Lease Liabilities Payments Due After Year Four LesseeOperatingLeaseLiabilitiesPaymentsDueAfterYearFour	1440000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4081000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	613000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3468000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	808000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	723000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1308000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1195000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	227712000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	43007000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184705000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	227712000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33663000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	194049000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	28034000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	37378000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	37378000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	37378000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7705000
CY2024Q1	cprx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	36832000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184705000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P6Y2M12D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P6Y6M
CY2023Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2024Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2024Q1	cprx	Accrued Non Clinical And Clinical Trial Expenses AccruedNonClinicalAndClinicalTrialExpenses	527000
CY2023Q4	cprx	Accrued Non Clinical And Clinical Trial Expenses AccruedNonClinicalAndClinicalTrialExpenses	1015000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5856000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4730000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4852000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8883000
CY2024Q1	cprx	Accrued License Fees Current AccruedLicenseFeesCurrent	8934000
CY2023Q4	cprx	Accrued License Fees Current AccruedLicenseFeesCurrent	24437000
CY2024Q1	cprx	Accrued Purchases Current AccruedPurchasesCurrent	694000
CY2023Q4	cprx	Accrued Purchases Current AccruedPurchasesCurrent	192000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	377000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369000
CY2024Q1	cprx	Accrued Gross To Net Revenue Liabilities AccruedGrossToNetRevenueLiabilities	24885000
CY2023Q4	cprx	Accrued Gross To Net Revenue Liabilities AccruedGrossToNetRevenueLiabilities	6877000
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	7340000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	729000
CY2024Q1	cprx	Asset Acquisation Due To Licensor Current AssetAcquisationDueToLicensorCurrent	12205000
CY2023Q4	cprx	Asset Acquisation Due To Licensor Current AssetAcquisationDueToLicensorCurrent	12540000
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1204000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1031000
CY2024Q1	cprx	Accrued Charitable Contributions AccruedCharitableContributions	1800000
CY2023Q4	cprx	Accrued Charitable Contributions AccruedCharitableContributions	0
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	631000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	465000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69305000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61268000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3091000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3188000
CY2024Q1	cprx	Asset Acquisation Due To Licensor Noncurrent AssetAcquisationDueToLicensorNoncurrent	1859000
CY2023Q4	cprx	Asset Acquisation Due To Licensor Noncurrent AssetAcquisationDueToLicensorNoncurrent	2497000
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	748000
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	485000
CY2024Q1	cprx	Other Noncurrent Accrued Expenses And Other Liabilities OtherNoncurrentAccruedExpensesAndOtherLiabilities	5698000
CY2023Q4	cprx	Other Noncurrent Accrued Expenses And Other Liabilities OtherNoncurrentAccruedExpensesAndOtherLiabilities	6170000
CY2024Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	75003000
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	67438000
CY2022Q3	cprx	License And Asset Purchase Agreement Payment Made In First Year LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear	10000000
CY2023Q3	cprx	License And Asset Purchase Agreement Payment Made In First Year LicenseAndAssetPurchaseAgreementPaymentMadeInFirstYear	10000000
CY2023Q1	cprx	Number Of Trading Days From Receipt Of The Notice Letter NumberOfTradingDaysFromReceiptOfTheNoticeLetter	P45D
CY2024Q1	cprx	Percentage Of Royalty Payable To Net Sales PercentageOfRoyaltyPayableToNetSales	0.035
CY2024Q1	cprx	Asset Acquisition Consideration Transferred Investments AssetAcquisitionConsiderationTransferredInvestments	13465000
CY2024Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	94978000
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.20
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.208
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	118029526
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	118029526
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107121549
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107121549
CY2024Q1	cprx	Number Of Votes Entitlement For Each Share Held By Common Stock Holders NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders	1
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8248000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2892000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14241187
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001193125-24-134195-index-headers.html	Edgar Link	pending
0001193125-24-134195-index.html	Edgar Link	pending
0001193125-24-134195.txt	Edgar Link	pending
0001193125-24-134195-xbrl.zip	Edgar Link	pending
cprx-20240331.xsd	Edgar Link	pending
d732534d10q.htm	Edgar Link	pending
d732534dex311.htm	Edgar Link	pending
d732534dex312.htm	Edgar Link	pending
d732534dex321.htm	Edgar Link	pending
d732534dex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
cprx-20240331_cal.xml	Edgar Link	unprocessable
cprx-20240331_def.xml	Edgar Link	unprocessable
cprx-20240331_lab.xml	Edgar Link	unprocessable
cprx-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
d732534d10q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPRX
CATALYST PHARMACEUTICALS, INC. Stock $cprx

2024 Q2 Form 10-Q Financial Statement

#000119312524134195 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPRX CATALYST PHARMACEUTICALS, INC. Stock $cprx

2024 Q2 Form 10-Q Financial Statement

#000119312524134195 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPRX
CATALYST PHARMACEUTICALS, INC. Stock $cprx